At a glance
ClinicalIndex Comparison Record- ✓Histologically confirmed colorectal adenocarcinoma with liver metastases
- ✓MSS/pMMR subtype
- ✓Previously received standard first- and second-line systemic anti-tumor therapy
- ✓At least one measurable lesion per RECIST 1.1
- ✕Other malignancies within 3 years prior to enrollment
- ✕Participating in other interventional clinical studies or receiving investigational drugs within past 4 weeks
- ✕Prior anti-PD-1, anti-PD-L1, anti-PD-L2, or T cell co-stimulatory/co-inhibitory receptor inhibitors
- ✕Prior fruquintinib
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Fruquintinib Combined With Sintilimab ± Radiotherapy for Third-line Treatment of Colorectal Cancer With Liver Metastases: A Randomized, Controlled, Multicenter Phase II Trial
In Brief
A Phase 2 clinical trial evaluating Immunotherapy (Sintilimab), Targeted Therapy Agent (Fruquintinib), and 1 other intervention for Colorectal Cancer and 4 related conditions. Currently recruiting, targeting 62 participants across 1 site.
Detailed Summary
Colorectal cancer (CRC) is a significant cause of morbidity and mortality worldwide. Its early clinical manifestations are often subtle, leading to late-stage diagnosis in about 30% of cases with distant metastases. Liver metastases are widespread and associated with poor prognosis, especially in terms of response to immunotherapy. This prospective study will evaluate the efficacy of combined therapy involving sintilimab, fruquintinib, and radiotherapy in CRC with liver metastases. The primary objectives are to assess progression-free survival, overall survival, and treatment response rates. This study aims to provide valuable insights into optimizing third-line and subsequent therapies for CRC with liver metastases by elucidating the efficacy and safety of this combined treatment approach.
Study Details
Timeline
Interventions
Sintilimab
Fruquintinib
SBRT and LDRT